Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by IvanVanBeethovenon Oct 16, 2023 8:15am

271 Views

Post# 35684907

PR: TLT Provides Update on Bladder Cancer Clinical Study

TLD 1433-2 Clinical Study (Evaluable Patients)
Assessment	90 Day	90 Day	180 Day	180 Day	270 Day	270 Day	360 Day	360 Day	450 Day	450 Day
Assessment	#	%	#	%	#	%	#	%	#	%
Complete Response ("CR")	33	58%	31	56%	23	46%	16	36%	14	33%
Indeterminate Response ("IR")	4	7%	8	15%	6	12%	2	4%	2	5%
Total Responders (CR and IR)	37	65%	39	71%	29	58%	18	40%	16	38%
Total Evaluated	57		55		50		45		42

Mr. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase® stated, "To date, the Theralase® Study II clinical data has demonstrated best-in-class performance for a single agent, providing high efficacy, durable response and a high safety profile, with no serious adverse events directly related to Ruvidar^TM or the TLC-3200 Medical Laser System. Theralase® hopes to complete patient enrollment with accompanying administration of the primary Study II Treatment by year end 2024. If successful, this will allow the Company the ability to complete assessment of the primary, secondary and tertiary endpoints of these patients by 2026. Based on the clinical data to date, Theralase® is investigating potential partnerships for commercialization, financing and distribution of this ACT technology on an international basis. Theralase® looks forward to commercializing this world-class technology for the benefit of all shareholders."

Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, "Theralase® is delighted in its latest clinical data analysis. The Theralase® Ruvidar^TM-based Anti-Cancer Therapy ("ACT") has shown remarkable single-agent activity by proving to be safe and effective on a very difficult to treat BCG-Unresponsive patient population that has been diagnosed with high-grade NMIBC CIS, with or without resected T_a / T₁ papillary tumours. These patients have failed the standard of care, such as BCG therapy and a large majority of them have failed treatment with various modern immunotherapy drugs. Theralase® has been able to demonstrate strong efficacy in the form of a CR or IR, with a well-tolerated safety profile, after predominately one treatment. This ACT technology, pending successful regulatory approval and commercialization, will be very attractive to patients, uro-oncologists and the insurance companies that insure these patients."